Latest papers

Duloxetine: clinical pharmacokinetics and drug interactions.

An overview of osteoporosis: from genetics to clinics.

Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.

Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

[Exploratory study on biomarkers associated with severe cutaneous adverse reactions].

Genomic and metabolomic patterns segregate with responses to calcium and vitamin D supplementation.

Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.

Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs.

Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Preemptive genotyping trialed to prevent adverse drug reactions.

[Prediction of postoperative pain gives new possibilities. Tailored pain relief can prevent development of prolonged severe pain].

No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression.

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.

Duke's Discovery Genomics center rides pharmacogenomics wave.

Is pharmacogenetic CYP2D6 testing useful?

Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.

SLC19A1 pharmacogenomics summary.

Useful genetic variation databases for oncologists investigating the genetic basis of variable treatment response and survival in cancer.